Gene: FOXO4

4303
AFX|AFX1|MLLT7
forkhead box O4
protein-coding
Xq13.1
Ensembl:ENSG00000184481 MIM:300033 Vega:OTTHUMG00000021789 UniprotKB:P98177
NG_016418.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KIF1C0.934
FBXW40.915
MCM70.914
ANKRD400.891
CENPB0.888
MAP40.876
MAP4K40.871
PKP40.868
C22orf460.866
TRIM410.862

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.479
OR4F5-0.396
LINGO2-0.371
LAMB1-0.369
CNTN5-0.366
RFX8-0.365
KMO-0.365
PCDH8-0.364
TNFRSF11A-0.362
HSPB3-0.362

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C07258116-hydroxycleroda-3,13(14)-dien-15,16-olide"16-hydroxycleroda-3,13(14)-dien-15,16-olide results in increased expression of FOXO4 mRNA"21530604
D000082AcetaminophenAcetaminophen affects the expression of FOXO4 mRNA17562736
D020106AcrylamideAcrylamide results in decreased expression of FOXO4 mRNA28959563
D020106AcrylamideAcrylamide results in increased expression of FOXO4 mRNA28959563
D000968Antimycin AAntimycin A results in decreased expression of FOXO4 protein24040102
D000968Antimycin A[FOXO1 protein co-treated with FOXO4 protein co-treated with FOXO3 protein] affects the reaction [resveratrol inhibits the reaction [Antimycin A results in increased expression of BAX protein]]24040102
D000968Antimycin AFOXO4 mutant form affects the reaction [[Antimycin A co-treated with resveratrol] affects the expression of SOD2 mRNA]24040102
D000968Antimycin AFOXO4 mutant form affects the reaction [[Antimycin A co-treated with resveratrol] affects the expression of SOD2 protein]24040102
D001280AtrazineAtrazine results in increased expression of FOXO4 mRNA22378314
D001280AtrazineAtrazine results in decreased expression of FOXO4 mRNA27614199
D001564Benzo(a)pyreneBenzo(a)pyrene affects the activity of FOXO4 protein20624995
C006780bisphenol Abisphenol A affects the methylation of FOXO4 promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of FOXO4 mRNA25181051
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of FOXO4 mRNA27510461
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of FOXO4 gene20938992
C480342clothianidinclothianidin results in decreased expression of FOXO4 mRNA29044138
D003300CopperCopper results in increased phosphorylation of FOXO4 protein16973122
D003300Copperwortmannin inhibits the reaction [Copper results in increased phosphorylation of FOXO4 protein]16973122
D019327Copper SulfateCopper Sulfate results in increased phosphorylation of FOXO4 protein16973122
D019327Copper Sulfatewortmannin inhibits the reaction [Copper Sulfate results in increased phosphorylation of FOXO4 protein]16973122
D016572CyclosporineCyclosporine results in decreased expression of FOXO4 mRNA25562108
C014347decitabinedecitabine affects the expression of FOXO4 mRNA23300844
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of FOXO4 mRNA]27941970
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of FOXO4 mRNA21266533
D002945CisplatinCisplatin affects the expression of FOXO4 mRNA23300844
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of FOXO4 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of FOXO4 mRNA27594783
D003633Dichlorodiphenyl DichloroethyleneDichlorodiphenyl Dichloroethylene results in increased activity of FOXO4 protein27589886
D004041Dietary FatsDietary Fats results in increased expression of FOXO4 mRNA25016146
D002117CalcitriolCalcitriol results in increased expression of FOXO4 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of FOXO4 mRNA21592394
C082360fipronilfipronil results in decreased expression of FOXO4 mRNA23962444
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of FOXO4 gene20938992
D004397FonofosFonofos results in increased methylation of FOXO4 promoter22847954
D006861Hydrogen Peroxide[Hydrogen Peroxide results in increased activity of RALA protein] which results in increased phosphorylation of and results in increased activity of and affects the localization of FOXO4 protein15538382
D006861Hydrogen PeroxideHydrogen Peroxide results in increased phosphorylation of and results in increased activity of and affects the localization of FOXO4 protein15538382
D006861Hydrogen PeroxideMAPK10 protein affects the susceptibility to [Hydrogen Peroxide results in increased phosphorylation of FOXO4 protein]15538382
D006861Hydrogen PeroxideMAPK8 protein affects the susceptibility to [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of FOXO4 protein]15538382
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of FOXO4 mRNA27392435
C544151jinfukangjinfukang results in increased expression of FOXO4 mRNA27392435
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of FOXO4 gene20938992
D009532NickelNickel results in decreased expression of FOXO4 mRNA24768652|2558310
D010100OxygenOxygen deficiency results in increased expression of FOXO4 mRNA22629407
D010100OxygenOxygen inhibits the reaction [Oxygen deficiency results in increased expression of FOXO4 mRNA]22629407
D010278ParathionParathion results in increased methylation of FOXO4 promoter22847954
C006253pirinixic acidpirinixic acid results in decreased expression of FOXO4 mRNA17950772
C006253pirinixic acidPPARA protein promotes the reaction [pirinixic acid results in decreased expression of FOXO4 mRNA]17950772
D011374ProgesteroneProgesterone results in increased expression of FOXO4 mRNA23012394
C045950propiconazolepropiconazole results in decreased expression of FOXO4 mRNA21278054
C059514resveratrolFOXO4 protein affects the reaction [resveratrol results in decreased expression of CCND1 protein]21179458
C059514resveratrolFOXO4 protein affects the reaction [resveratrol results in increased expression of BCL2L11 protein alternative form]21179458
C059514resveratrolFOXO4 protein affects the reaction [resveratrol results in increased expression of CDKN1B protein]21179458
C059514resveratrolFOXO4 protein affects the reaction [resveratrol results in increased expression of TNFRSF10A protein]21179458
C059514resveratrolFOXO4 protein affects the reaction [resveratrol results in increased expression of TNFRSF10B protein]21179458
C059514resveratrolFOXO4 protein results in decreased susceptibility to resveratrol20012470
C059514resveratrolresveratrol inhibits the reaction [INS protein results in increased phosphorylation of FOXO4 protein]17550345
C059514resveratrolresveratrol results in decreased phosphorylation of FOXO4 protein21179458
C059514resveratrolresveratrol promotes the reaction [SIRT1 protein results in increased activity of FOXO4 protein]16012755
C059514resveratrolresveratrol results in increased activity of FOXO4 protein16012755
C059514resveratrol[resveratrol results in increased activity of SIRT1 protein] promotes the reaction [SIRT1 protein binds to and results in decreased acetylation of and results in increased activity of FOXO4 protein]16012755
C059514resveratrol[FOXO1 protein co-treated with FOXO4 protein co-treated with FOXO3 protein] affects the reaction [resveratrol inhibits the reaction [Antimycin A results in increased expression of BAX protein]]24040102
C059514resveratrolFOXO4 mutant form affects the reaction [[Antimycin A co-treated with resveratrol] affects the expression of SOD2 mRNA]24040102
C059514resveratrolFOXO4 mutant form affects the reaction [[Antimycin A co-treated with resveratrol] affects the expression of SOD2 protein]24040102
C059514resveratrolresveratrol results in increased expression of FOXO4 protein24040416
C059514resveratrolFOXO4 protein affects the reaction [resveratrol results in increased expression of TNFSF10 protein]21179458
C059514resveratrolFOXO4 protein affects the susceptibility to resveratrol21179458
C059514resveratrolresveratrol results in increased activity of FOXO4 protein mutant form21179458
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of FOXO4 mRNA25895662
C061133tamibarotenetamibarotene results in increased expression of FOXO4 mRNA15498508
C012568terbufosterbufos results in increased methylation of FOXO4 promoter22847954
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of FOXO4 mRNA21592394
D013739TestosteroneTestosterone results in decreased expression of FOXO4 mRNA21592394
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FOXO4 mRNA24058054
D014050TolueneToluene results in decreased expression of FOXO4 mRNA22967744
D014212TretinoinTretinoin results in increased expression of FOXO4 mRNA15498508
D014212TretinoinTretinoin results in decreased expression of FOXO4 mRNA20488242
C012589trichostatin Atrichostatin A affects the expression of FOXO4 mRNA28542535
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of FOXO4 mRNA29024780
D014520UrethaneUrethane results in increased expression of FOXO4 mRNA28818685
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of FOXO4 gene25560391
D009536NiacinamideNiacinamide inhibits the reaction [SIRT1 protein results in increased activity of FOXO4 protein]16012755
D009536NiacinamideNiacinamide results in decreased activity of FOXO4 protein16012755
C009687wortmanninwortmannin inhibits the reaction [Copper results in increased phosphorylation of FOXO4 protein]16973122
C009687wortmanninwortmannin inhibits the reaction [Copper Sulfate results in increased phosphorylation of FOXO4 protein]16973122
C009687wortmanninwortmannin inhibits the reaction [Zinc results in increased phosphorylation of FOXO4 protein]16973122
C009687wortmanninwortmannin inhibits the reaction [Zinc Sulfate results in increased phosphorylation of FOXO4 protein]16973122
D015032Zincwortmannin inhibits the reaction [Zinc results in increased phosphorylation of FOXO4 protein]16973122
D015032ZincZinc results in increased phosphorylation of FOXO4 protein16973122
D019287Zinc Sulfatewortmannin inhibits the reaction [Zinc Sulfate results in increased phosphorylation of FOXO4 protein]16973122
D019287Zinc SulfateZinc Sulfate results in increased phosphorylation of FOXO4 protein16973122

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-IBA21873635  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IC-  
GO:0003677DNA binding-IDA10783894  
GO:0003700DNA-binding transcription factor activity-IBA21873635  
GO:0003700DNA-binding transcription factor activity-IDA10783894  
GO:0005515protein binding-IPI15084259  15126506  16114898  25416956  
GO:0008013beta-catenin binding-IDA15905404  
GO:0008134transcription factor binding-IBA21873635  
GO:0008134transcription factor binding-IPI16054032  
GO:0019899enzyme binding-IPI15126506  16964248  
GO:0042802identical protein binding-IPI25609649  
GO:0043565sequence-specific DNA binding-IBA21873635  
GO:0043565sequence-specific DNA binding-IDA23332764  
GO:0043565sequence-specific DNA binding-IMP22972301  
GO:1990841promoter-specific chromatin binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IBA21873635  
GO:0006355regulation of transcription, DNA-templated-IDA15126506  
GO:0006366transcription by RNA polymerase II-TAS10783894  
GO:0007050cell cycle arrest-IDA10783894  
GO:0007095mitotic G2 DNA damage checkpoint-IEA-  
GO:0007517muscle organ development-IEA-  
GO:0007568aging-IEA-  
GO:0008285negative regulation of cell proliferation-IDA10783894  
GO:0008286insulin receptor signaling pathway-IBA21873635  
GO:0008286insulin receptor signaling pathway-IDA10217147  
GO:0014911positive regulation of smooth muscle cell migration-IEA-  
GO:0016525negative regulation of angiogenesis-IDA12761217  
GO:0016579protein deubiquitination-TAS-  
GO:0031667response to nutrient levels-IEA-  
GO:0042593glucose homeostasis-IBA21873635  
GO:0045944positive regulation of transcription by RNA polymerase II-IBA21873635  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA11689711  15905404  
GO:0048863stem cell differentiation-IMP22972301  
GO:0051151negative regulation of smooth muscle cell differentiation-IDA16054032  
GO:0070317negative regulation of G0 to G1 transition-IDA10783894  
GO:0071158positive regulation of cell cycle arrest-IDA15905404  
GO:1990785response to water-immersion restraint stress-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA16272144  16964248  
GO:0005634nucleus-TAS22972301  
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA16964248  
GO:0005829cytosol-IDA16272144  
GO:0005829cytosol-TAS22972301  
GO:0016607nuclear speck-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-1643685DiseaseTAS
R-HSA-198693AKT phosphorylates targets in the nucleusTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5674400Constitutive Signaling by AKT1 E17K in CancerTAS
R-HSA-5688426DeubiquitinationTAS
R-HSA-5689880Ub-specific processing proteasesTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-9006925Intracellular signaling by second messengersTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24935588Low expression of the FoxO4 gene may contribute to the phenomenon of EMT in non-small cell lung cancer. (2014)Xu MMAsian Pac J Cancer Prev
26373813Differential Contributions of Alcohol and Nicotine-Derived Nitrosamine Ketone (NNK) to White Matter Pathology in the Adolescent Rat Brain. (2015 Nov)Tong MAlcohol Alcohol